• Life Sciences and Healthcare
  • Clear
  • Most Recent
  • Most Relevant
85 results
Alert
Ninth Circuit Relaxes Standard for Pleading Federal Trade Secrets Claims in California
The First 100 Days podcast episode banner
Podcast
07: IP policy through an “America first” lens
Charting the course for US innovation
Petri dish
Alert
Life Science & Healthcare Private Capital Risk: Q2 2025 Update
Pills and tables
Insight
Healthy returns: European life sciences M&A heats up as sector faces demographic reckoning
M&A Explorer | Dealmaking in Europe's life sciences sector has been relatively muted in recent years, but the first half of 2025 has shown signs of strength as companies respond to the stark realities of an aging population
Alert
New EU Responsibility and Liability Landscape for Smart Medical Devices in a Global Context
Alert
DOJ and HHS Relaunch False Claims Act Working Group, Sharpen Healthcare Enforcement Priorities
Alert
Federal Circuit Reinforces Standard for Prior Art Enablement in CRISPR Dispute
Alert
Arkansas Bans PBMs from Owning Pharmacies, Escalating Scrutiny of Vertical Integration in Pharmacy Distribution
Alert
Federal Circuit Clarifies Standard for Patent Conception in Ongoing CRISPR Dispute
Alert
AI’s Expanded Role in the Life Sciences Regulatory Review Process: Key Developments in U.S. and EU
Alert
FDA Foreign Inspections: Key developments and strategic shifts
Petri dish
Alert
Life Science Private Equity Risk
Alert
Trump Administration Initiates Section 232 Investigations on Pharmaceuticals and Semiconductors
Alert
China Released First-of-Its-Kind Compliance Guidelines for Healthcare Companies to Prevent Commercial Bribery Risks
Alert
The CMA’s “revised” approach to UK merger control and impact on M&A
Alert
First International Procurement Instrument case relating to EU medical devices in China’s public procurement market. The key question is what comes next?
Alert
UK expands its merger control regime and the CMA’s powers with the Digital Markets, Competition & Consumers Act
Alert
United States Finalizes Section 301 Tariff Increases on Imports from China
Alert
Australia’s proposed mandatory merger notification thresholds announced
Article
The Current Status of FTC’s Orange Book Listings Challenge: A Mixed Bag
Article
United States: Pharmaceutical Antitrust 2025
Alert
Federal Circuit Limits the Application of Obviousness-Type Double Patenting for Patents in the Same Family
Alert
Three Drug Pricing Litigation Issues to Watch in the Second Half of 2024
Alert
Merger reform exposure draft proposes broad competition law reform
Alert
USTR Issues Details of the Proposed Section 301 China Tariff Increases, Seeking Public Input
Alert
Biden Administration Expands Section 301 Tariffs on Imports from China, Targeting Green Energy, Metals, Minerals, Port Cranes, Medical Supplies, and Semiconductors
Article
German financing market ready to reset after a challenging year
Event
ABA 2024 Antitrust Spring Meeting
Alert
DOJ Antitrust Division Announces Deferred Prosecution Agreements with Two Pharmaceutical Companies Containing “Extraordinary” Divestiture Remedy
Article
United States: Pharmaceutical Antitrust 2024
Alert
Where Things Stand on Drug Pricing at the Halfway Point of 2023
Close up shot of pipette tips
Insight
European biotech enjoys a burst of dealmaking activity
M&A Explorer | The first quarter saw a string of transactions after a punishing year for the sector
Birds eye view of a skyscrapers
Insight
Tech continues to dominate
Last year was a volatile 12 months for the tech sector, with a steep sell-off in growth stocks and a drop in IPOs—but, although the sector was down, it was by no means out
Alert
EU Court of Justice clarifies that all exchanges with external counsel are privileged – an important development amidst a dawn raid uptick in Europe
Medicine
Insight
PMB performs as pharma groups repurpose their portfolios
After a year of historic profits in 2021 following the mass roll-out of COVID-19 vaccines and related treatments, big pharma companies armed with cash for deals have been shifting their attention
healthcare tubes
Insight
Global healthcare M&A delivers strong performance
M&A Explorer | Dealmaking in the pharma, medical and biotech (PMB) subsectors was driven by both old and new market trends in 2022
Alert
Five Drug Pricing Issues to Watch in 2023
Alert
Strong Medicine: Using Investment Treaties to Mitigate Foreign Regulatory Risk in the Life Sciences
Article
United States: Pharmaceutical Antitrust 2023
Alert
2022 Drug Pricing Update: States Continue Legislative Push Even As Congress Passes Long Sought Changes